ARCHIVES

Samuel Waksal Resigns From ImClone Following Unimpressive ASCO Presentation

This article is from The Cancer Letter archive.

Vol. 28 No. 21 | May 24, 2002

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Concepts Of Eight New Biological Response Modifiers Program

July 3, 1981

In Brief: Louisville Cancer Center Developed With No Federal, State Money Or Fund Raising Costs

May 30, 1980

DCT Issues New Program Announcement On Clinical Research

December 5, 1980

ACS Awards Grants To Wisconsin, USC For Behavior Research

July 16, 1993

NCI Encourages IP Chemo For Stage III Ovarian Cancer

January 27, 2006

Recommendation By Patients; report Of Protocol Committee

August 9, 1996